Solid Biosciences Inc. (SLDB) company profile
Close on Nov 17, 2026Market cap $668.01MP/E –Yield –
About Solid Biosciences
Biological Products, (No Diagnostic Substances), SIC 2836
Solid Biosciences Inc. is a life sciences company that develops gene therapies for rare neuromuscular and cardiac diseases. Its research and development efforts focus on gene transfer candidates designed to deliver functional transgenes to treat conditions caused by mutated genes. The company's pipeline includes investigational therapies such as SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for dilated cardiomyopathy. Because its pipeline remains in development, the company does not currently sell commercial products, and its target end-users are patients suffering from these conditions.
The company's principal executive offices and laboratory spaces are located in Charlestown, Massachusetts. Solid Biosciences operates in the United States and relies on external contract manufacturers to produce its drug candidates. Additionally, the company maintains collaborative and licensing relationships with domestic academic centers and medical organizations, including the Mayo Clinic, the University of Florida, and the University of Washington.
Summary of the business section of Solid Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Solid Biosciences Inc.
- Founded
- 2013
- Headquarters
- Charlestown, MA
- Address
- 500 Rutherford Avenue, 3rd Floor 02129
- Phone
- (617) 337-4680
- Website
- solidbio.com
- Employees
- 121, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- SLDB
- Exchange
- Nasdaq
- IPO date
- Jan 29, 2018
- Shares outstanding
- 107M, Aug 4, 2026
- Public float
- $317.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Oct 28, 2022
- SEC CIK
- 1707502
- CUSIP
- 83422E204
- ISIN
- US83422E2046
- FIGI
- BBG00JN4FXG8
- Share class FIGI
- BBG00JN4FXH7
- EIN
- 90-0943402
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alexander Cumbo | President and CEO, Director | 235,405 |
| Gabriel Brooks | Chief Medical Officer | 97,241 |
| Kevin Tan | CFO & Treasurer | 99,422 |
| Jessie Hanrahan | Chief Regulatory Officer | 74,318 |
| Paul Herzich | Chief Technology Officer | 72,638 |
| David T. Howton | Chief Operating Officer | 105,077 |
| Ilan Ganot | Director | 146,165 |
| Ian F. Smith | Director | 141,585 |
| Clare Kahn | Director | 2,960 |
| Advisors Llc Perceptive | Director | 6,749,803 |
| Life Sciences Master Fund Ltd Perceptive | Director | – |
| Joseph Edelman | Director | 11,833,539 |
| Adam Leo Stone | Director | 0 |
| Sukumar Nagendran | Director | 34,258 |
| Lynne Marie Sullivan | Director | – |
| Martin I. Freed | Director | 53,763 |
| Georgia Keresty | Director | – |
| Perceptive Xontogeny Venture Fund, LP | Director | 6,833,539 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.22M | $7.79M | $2.46M | $105 | – |
| FY2024 Alexander Cumbo | $4.87M | $3.45M | $2.32M | $74 | – |
| FY2024 Ilan Ganot | $0 | $0 | $2.32M | $74 | – |
| FY2023 Alexander Cumbo | $918.63K | $862.41K | $1.18M | $114 | – |
| FY2023 Ilan Ganot | $0 | $0 | $1.18M | $114 | – |
| FY2022 | $2.20M | $1.63M | $1.08M | $21 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Alexander Cumbo President and Chief Executive Officer | $650.99K | $449.18K | $2.32M | $1.79M | $12.60K | $5.22M | +7% |
| Gabriel Brooks, M.D. Chief Medical Officer | $502.16K | $259.87K | $798.63K | $756.79K | $10.70K | $2.33M | +12% |
| David Tyronne Howton Chief Operating Officer and Secretary | $513.42K | $265.70K | $1.00M | $796.62K | $12.60K | $2.59M | +1% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 29, 2018
- Offer price
- $16.00
- Securities offered
- 7,812,500
- Gross proceeds
- $125.00M
- Exchange
- Nasdaq
- First trading day
- Jan 26, 2018
- First-day close
- $22.62+41.4%
- Lock-up ends (est.)
- Jul 25, 2018
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 121 full-time employees, including 89 in research and development and 32 in general and administrative positions, and of which 26 of our employees hold Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 5, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 7, 2022 | Merger vote | Definitive merger proxy statement |
| Jun 6, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 29, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 25, 2018 | Name change | Name changed from Solid Biosciences, LLC to Solid Biosciences Inc. |
| Jan 22, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?